BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28992528)

  • 1. Adjuvant therapy in renal cell carcinoma.
    Massari F; Di Nunno V; Ciccarese C; Graham J; Porta C; Comito F; Cubelli M; Iacovelli R; Heng DYC
    Cancer Treat Rev; 2017 Nov; 60():152-157. PubMed ID: 28992528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Targeted Therapy Influence Renal Surgery for Renal Cell Carcinoma.
    Greco F; Marchioni M; Esperto F; Papalia R; Schips L; Scarpa RM
    Curr Drug Targets; 2020; 21(15):1550-1557. PubMed ID: 32621715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
    Choueiri M; Tannir N; Jonasch E
    Curr Clin Pharmacol; 2011 Aug; 6(3):144-50. PubMed ID: 21827393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
    Mehrazin R; Tsao CK; Sfakianos J; Galsky MD
    Urol Oncol; 2016 May; 34(5):221-4. PubMed ID: 26997518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
    Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
    Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
    Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
    Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
    Merza H; Bilusic M
    Curr Oncol Rep; 2017 Apr; 19(4):27. PubMed ID: 28303494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
    Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for advanced renal cell carcinoma.
    Meissner MA; McCormick BZ; Karam JA; Wood CG
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeted therapies for renal cell carcinoma.
    Graham SD; Warden ME; Lou J
    Can J Urol; 2007 Dec; 14 Suppl 1():48-52. PubMed ID: 18163945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing novel immunocombinations in metastatic renal cell carcinoma.
    Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
    Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers?
    Grassi P; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):803-4. PubMed ID: 27322839
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.
    Porta C; Chiellino S; Ferrari A; Mariucci S; Liguigli W
    Expert Opin Pharmacother; 2017 Feb; 18(2):205-216. PubMed ID: 28103447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
    Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
    Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
    Buti S; Bersanelli M; Sikokis A; Maines F; Facchinetti F; Bria E; Ardizzoni A; Tortora G; Massari F
    Anticancer Drugs; 2013 Jul; 24(6):535-54. PubMed ID: 23552469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
    Grünwald V
    Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.